NCT04351347.

Methods	Trial design: open‐label RCT with 2 parallel arms Type of record: trial register entry Sample size: 300 Setting: NR Country: Egypt Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NCT04351347 Date of registration: 17 April 2020
Participants	Inclusion criteria People with COVID‐19 Exclusion criteria Allergy or adverse effects to treatment
Interventions	Details of intervention Type and dose: ivermectin, no details on dosing and frequency scheme Route of administration: oral Treatment details of control group Standard of care, no details provided Concomitant therapy: NR
Outcomes	Primary study outcome Number of participants with improvement or death within 1 month Relevant review outcomes planned Mortality at 30 days Additional study outcomes None
Notes	Reason for awaiting classification: unclear if standard of care administered in ivermectin arm; unclear if RT‐PCR confirmed diagnosis at enrolment; unclear healthcare setting Recruitment status: recruiting Prospective completion date: 1 December 2030 Date last update posted: 10 March 2021 Sponsor/funding: Tanta University